Ireland - English - HPRA (Health Products Regulatory Authority)

new haven pharma (uk) limited - acetylsalicylic acid - prolonged-release capsule, hard - 162.5 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - acetylsalicylic acid - gastro-resistant tablet - 75 milligram(s) - platelet aggregation inhibitors excl. heparin; acetylsalicylic acid - antithrombotic agents: platelet aggregation inhibitors excl. heparin - it is used for: secondary prevention of myocardial infarction, prevention of cardiovascular morbidity in patients suffering from stable angina pectoris, history of unstable angina pectoris, except during the acute phase, prevention of graft occlusion after coronary artery bypass grafting (cabg), coronary angioplasty, except during the acute phase, secondary prevention of transient ischaemic attacks (tia) and ischaemic cerebrovascular accidents (cva), provided intracerebral haemorrhages have been ruled out.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - acetylsalicylic acid; caffeine; paracetamol - film-coated tablet - 300/200/45 milligram(s) - salicylic acid and derivatives; acetylsalicylic acid, combinations excl. psycholeptics

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

bayer sa-nv - acetylsalicylic acid 400 mg - effervescent tablet - 400 mg - 240 mg - acetylsalicylic acid 400 mg; ascorbic acid 240 mg - acetylsalicylic acid, combinations excl. psycholeptics

Malta - English - Medicines Authority

wockhardt uk limited - acetylsalicylic acid - gastro-resistant tablet - acetylsalicylic acid 75 mg - antithrombotic agents

Malta - English - Medicines Authority

pinewood laboratories limited ballymacarbry, clonmel, co. tipperary, ireland - acetylsalicylic acid - gastro-resistant tablet - acetylsalicylic acid 75 mg - antithrombotic agents

European Union - English - EMA (European Medicines Agency)

teva pharma b.v. - ibandronic acid - breast neoplasms; neoplasm metastasis; fractures, bone; osteoporosis, postmenopausal - drugs for treatment of bone diseases - ibandronic acid 50mgibandronic acid teva is indicated for the prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases.ibandronic acid 150mgtreatment of osteoporosis in postmenopausal women at increased risk of fracture. a reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.

Israel - English - Ministry of Health

gsk consumer healthcare, israel ltd - acetylsalicylic acid; caffeine; paracetamol - caplets - paracetamol 250 mg; acetylsalicylic acid 250 mg; caffeine 65 mg - paracetamol, combinations excl. psycholeptics - paracetamol, combinations excl. psycholeptics - for temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.

Israel - English - Ministry of Health

gsk consumer healthcare, israel ltd - acetylsalicylic acid; caffeine; paracetamol - caplets - paracetamol 250 mg; acetylsalicylic acid 250 mg; caffeine 65 mg - paracetamol, combinations excl. psycholeptics - for temporary relief of the pain of headache, mild to moderate pain associated with migraine headache, pain of menstrual descomfort and pain accompanied by fever.

United States - English - NLM (National Library of Medicine)

nationwide laboratories, llc - salicylic acid (unii: o414pz4lpz) (salicylic acid - unii:o414pz4lpz) - salicylic acid 6 g in 100 ml - for dermatologic  use: salicylic acid 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked  and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and  psoriasis (including body, scalp, palms and soles). for podiatric use: salicylic  acid 6% is a topical aid in the removal of excessive keratin on  dorsal and plantar hyperkeratotic  lesions. topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. salicylic acid 6% should not be used in any patient known to be sensitive to salicylic acid or any other listed ingredients. salicylic acid 6% should not be used in children under 2 years of age.